Welcome to our dedicated page for Redhill Biopharm SEC filings (Ticker: RDHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The RedHill Biopharma Ltd. (Nasdaq: RDHL) SEC filings page on Stock Titan provides centralized access to the company’s Form 20-F annual reports and Form 6-K current reports, which together document its regulatory, clinical, commercial and financing activities. As a foreign private issuer focused on gastrointestinal diseases, infectious diseases and oncology, RedHill uses Form 6-K extensively to furnish press releases and other information to the U.S. Securities and Exchange Commission.
In these filings, investors can review detailed disclosures about Talicia®, RedHill’s FDA-approved oral therapy for Helicobacter pylori infection in adults, including its indication, QIDP-based market exclusivity, patent coverage and ex-U.S. licensing arrangements. Filings also describe the company’s late-stage development programs: opaganib (ABC294640), a sphingosine kinase-2 selective inhibitor with anticancer, anti-inflammatory and antiviral activity; RHB-102 (Bekinda®), an extended-release ondansetron formulation for multiple gastrointestinal and oncology-support indications; RHB-204, an optimized formulation of RHB-104 for Crohn’s disease and pulmonary nontuberculous mycobacteria disease; and RHB-107 (upamostat), a host-directed serine protease inhibitor in late-stage development for non-hospitalized symptomatic COVID-19 and other conditions.
RedHill’s Form 6-K reports also cover capital markets and financing transactions, such as at-the-market offering programs, purchase agreements for American Depositary Shares, and amendments to ownership thresholds. Additional filings document Nasdaq listing compliance matters, including notifications related to the minimum stockholders’ equity requirement and subsequent confirmation of regained compliance, as well as legal proceedings like New York Supreme Court judgments and Korean court attachment orders in the Kukbo dispute.
Stock Titan’s interface is designed to surface these filings as they are furnished to EDGAR and to pair them with AI-powered summaries that explain the key points of lengthy documents. Users can quickly identify items such as quarterly and interim financial information, registration statement incorporations by reference, and governance or financing updates, while drilling down into full-text filings when more detail is needed.
RedHill Biopharma disclosed it is not in compliance with Nasdaq Listing Rule 5550(b), which requires minimum stockholders' equity of $2,500,000. Nasdaq notified the Company of the deficiency on April 15, 2025 and on August 8, 2025 granted an extension giving the Company until October 13, 2025 to regain compliance.
The Company has submitted a plan to Nasdaq to restore compliance; if it does not meet the requirement by the extension date it may appeal to a Hearings Panel for additional time. The filing also notes that forward-looking statements about achieving compliance depend on market conditions and the satisfaction and closing of financing arrangements referenced in other filings.
RedHill Biopharma (Nasdaq: RDHL) filed a Form 6-K announcing positive FDA Type C meeting feedback for RHB-204, its next-generation, orally administered triple-antibiotic for Crohn’s disease (CD). The Agency agreed to a first-ever Phase 2 trial in MAP-positive CD patients, with co-primary endpoints of mucosal remission and MAP eradication. Use of rapid MAP diagnostics from two academic partners allows a smaller sample size, meaning lower cost and faster completion.
RHB-204 is protected by patents to 2041 and leverages Phase 3 data from predecessor RHB-104 that showed a 64 % efficacy improvement versus standard of care. Management plans to fund the study through non-dilutive grants/partnerships and pursue additional FDA designations (orphan, breakthrough, fast track) that could confer exclusivity and priority review vouchers. The Crohn’s market is forecast to expand from $13.6 bn in 2024 to $19 bn in 2033, creating significant commercial upside if the program succeeds. Key risks remain: trial execution, securing external funding, and eventual regulatory approval.
RedHill Biopharma has filed an F-1 registration statement for a potential offering of up to 5,596,490 American Depositary Shares (ADSs) representing 55,964,900,000 ordinary shares. The offering relates to resale by Alumni Capital LP through an Any Market Purchase Agreement dated June 20, 2025.
Key offering details:
- Committed equity line of credit up to $10 million with Alumni Capital
- Each ADS represents 10,000 ordinary shares
- Includes 5,263,157 AMPA ADSs and 333,333 Commitment Warrant ADSs
- Purchase price varies based on VWAP: 82% for initial purchase, 90% for regular purchases, or 96% for forward purchases
The company is an Israeli-based foreign private issuer trading on Nasdaq under "RDHL". RedHill will not receive proceeds from ADS resales but will receive proceeds from warrant exercises. Alumni Capital is considered an underwriter and subject to a 4.99% ownership limitation. The last reported ADS price was $1.94 on June 24, 2025.
RedHill Biopharma has entered into an Any Market Purchase Agreement with Alumni Capital LP on June 20, 2025, enabling the company to sell up to $10 million in American Depositary Shares (ADSs). Key terms include:
- Initial tranche up to $1 million priced at 82% of lowest 5-day VWAP
- Subsequent regular purchases up to $500,000 or 60% of 5-day average trading volume at 90% of lowest 5-day VWAP
- Additional discretionary purchases up to $500,000 or 30% of same-day trading volume at 96% of lowest traded price
- Commitment Warrants issued to purchaser for 333,333 ADSs with $3.00 exercise price and 5-year term
The agreement includes a 4.99% ownership cap and requires SEC registration effectiveness. The arrangement provides RedHill with flexible funding options through June 30, 2026, subject to market conditions and company discretion.